XPO1 and Hutchinson-Gilford progeria syndrome: Accordingly, we treated dermal fibroblasts derived from HGPS patients and the LMNAG609G/G609G mouse with the first‐ in‐ class selective inhibitor of CRM1 termed selinexor (Landes et al. 2023), and investigated the beneficial effects of this therapeutic agent at cellular and organismal levels.